This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with
SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.
Drug: 18F-αvβ6-BP
Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
Inclusion Criteria:
- Men and women age ≥ 18 yrs
- Diagnosed with SARS CoV2
- Must have 2 sequential COVID negative tests prior to each scan
- Must have no previous lung disease prior to SARS CoV2 infection
- Lung image (Xray or CT) taken during infectious/ diagnosis period
- Will sign the IRB-approved consent form
- Able to remain motionless for up to 30-60 minutes per scan.
Exclusion Criteria:
- Life expectancy <3 mo
- Women who are pregnant or breast-feeding
- Patients who cannot undergo PET/CT scanning because of weight limits(>350lbs)
- Lack of availability for follow-up assessments
- Re-infection with SARS CoV2 between scan sessions
- Other active infectious respiratory illness
University of California Davis
Sacramento, California, United States